| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | PR; NR3C3 |
| Entrez GeneID | 5241 |
| clone | 2E4B9 |
| WB Predicted band size | 99KDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human PGR (AA:166-411) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于PGR(孕酮受体)抗体的3篇代表性文献摘要，涵盖其应用及研究背景：
---
1. **文献名称**：*Monoclonal antibodies to human progesterone receptor: characterization and clinical applications*
**作者**：Horwitz KB, et al.
**摘要**：该研究开发了针对人孕酮受体(PGR)的单克隆抗体，用于检测乳腺癌组织中PGR的表达水平，为激素治疗反应提供预测依据。研究验证了抗体在免疫组化(IHC)和Western blot中的特异性，并证实PGR阳性患者对他莫昔芬治疗更敏感。
---
2. **文献名称**：*Comparison of progesterone receptor antibodies reveals systemic differences in immunohistochemical assay performance*
**作者**：Hewitt SM, et al.
**摘要**：通过对比不同克隆号(如1A6、636)的PGR抗体在乳腺癌组织中的检测效果，发现抗体选择显著影响染色结果。研究强调了标准化抗体使用对临床诊断一致性的重要性，并推荐特定克隆号用于精准检测。
---
3. **文献名称**：*Progesterone receptor isoforms in normal and pathological endometrium: regulation by sex steroids*
**作者**：Mote PA, et al.
**摘要**：探讨PGR-A和PGR-B亚型在子宫内膜中的表达差异及激素调控机制。通过特异性抗体区分亚型，发现PGR-B在增殖期高表达，而PGR-A在分泌期占主导，提示其在生殖生理及疾病(如子宫内膜癌)中的不同作用。
---
**备注**：如需更近期文献(如近5年)，可补充关于PGR抗体在单细胞测序或多组学分析中的新技术应用研究。
**Background of PGR Antibodies**
Progesterone receptor (PGR) antibodies are essential tools in studying and diagnosing hormone-responsive tissues and diseases, particularly in breast and reproductive cancers. PGR, a nuclear receptor encoded by the *PGR* gene, exists as two main isoforms, PRA and PRB, generated via alternative promoter usage. These receptors mediate progesterone’s effects, regulating gene expression involved in menstrual cycle regulation, pregnancy maintenance, and mammary gland development.
In clinical pathology, PGR antibodies are widely used in immunohistochemistry (IHC) to assess receptor expression in tumor tissues. In breast cancer, PGR status—alongside estrogen receptor (ER)—is a critical biomarker for molecular subtyping and treatment guidance. Tumors expressing PGR are typically hormone-sensitive, indicating potential responsiveness to endocrine therapies like tamoxifen or aromatase inhibitors. PGR positivity is also associated with favorable prognosis and lower aggressiveness.
Research highlights PGR's dual role: PRB promotes cell proliferation and differentiation, while PRA may inhibit these effects. Dysregulated PGR expression is linked to endocrine resistance, tumor progression, and gynecological disorders like endometriosis. Beyond oncology, PGR antibodies aid in studying normal physiology, such as endometrial remodeling and ovarian function.
Despite advancements, challenges remain, including standardization of IHC scoring and understanding isoform-specific roles. Ongoing studies aim to refine PGR’s predictive value and explore its interplay with other signaling pathways, enhancing personalized therapeutic strategies.
×
